600518.SHG Kangmei Pharmaceutical Co Ltd
- Market cap
- CNY 18.9B
- P/E
- 137.0x
- P/B
- 2.51x
- ROE
- 1.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600518.SHG undervalued?
Graham numberThe Graham number of Kangmei Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kangmei Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Kangmei Pharmaceutical Co Ltd yet.
Kangmei Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. It also engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, me…
Full company profileKangmei Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kangmei Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.6B | 17.6B | 17.1B | 11.4B | 5.41B | 4.15B | 4.18B | 4.87B | 5.19B | 5.25B | 4.70B |
| Gross Profit | 6.45B | 6.76B | 5.38B | 948M | -23.6B | 91.5M | 431M | 729M | 653M | 1.05B | 1.01B |
| Operating Income | 3.96B | 2.89B | 687M | -3.87B | -30.5B | 10.1B | -1.78B | 86.7M | -24.8M | 112M | -22.0M |
| EBITDA | 4.99B | 4.34B | 2.97B | -1.01B | -26.1B | -2.49B | -730M | 471M | -132M | 373M | 140M |
| Net Income | 3.34B | 2.15B | 374M | -4.66B | -31.1B | 7.92B | -2.69B | 103M | 8.57M | 10.3M | 125M |
| EPS | 0.67 | 0.39 | 0.08 | -0.94 | -6.29 | 0.57 | -0.19 | 0.01 | 0.00 | 0.00 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 54.8B | 65.3B | 73.1B | 64.6B | 33.3B | 16.1B | 15.1B | 14.3B | 13.8B | 13.2B | 12.9B |
| Total Liabilities | 25.4B | 36.8B | 47.0B | 43.9B | 43.7B | 6.09B | 8.18B | 7.20B | 6.59B | 5.89B | 5.49B |
| Shareholders' Equity | 29.1B | 28.4B | 25.6B | 20.5B | -10.5B | 9.93B | 6.95B | 7.05B | 7.17B | 7.29B | 7.38B |
| Cash & Short-term Investments | 27.3B | 4.21B | 1.84B | 507M | 552M | 2.42B | 1.51B | 1.06B | 978M | 1.24B | 1.36B |
| Total Debt | 13.1B | 22.2B | 29.0B | 32.9B | 31.1B | 205M | 264M | 214M | 111M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.60B | -4.84B | 306M | 2.88B | 1.03B | 214M | -750M | -318M | -428M | 111M | - |
| Capital Expenditure | 1.57B | 2.15B | 4.59B | 473M | 302M | 172M | 48.1M | 99.7M | 61.7M | 217M | 58.1M |
| Free Cash Flow | 35.8M | -305M | -4.29B | 2.41B | 730M | 42.6M | -798M | -417M | -489M | -106M | 72.4M |
| Ratios | |||||||||||
| ROE | 11.5% | 7.6% | 1.5% | -22.7% | - | 79.8% | -38.7% | 1.5% | 0.1% | 0.1% | 1.7% |
| ROA | 6.1% | 3.3% | 0.5% | -7.2% | -93.3% | 49.3% | -17.8% | 0.7% | 0.1% | 0.1% | 1.0% |
| Net Profit Margin | 15.4% | 12.2% | 2.2% | -40.7% | -574.4% | 190.7% | -64.3% | 2.1% | 0.2% | 0.2% | 2.6% |
| Debt to Equity | 0.45x | 0.78x | 1.14x | 1.61x | - | 0.02x | 0.04x | 0.03x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kangmei Pharmaceutical Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 28, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 750K | 0.00 | 8.7% |
| 2023 | - | - | - |
| 2022 | CNY 897K | 0.00 | - |
| 2021 | CNY 13.8M | 0.00 | 0.2% |
| 2020 | CNY 1.03B | 0.21 | - |
| 2019 | CNY 2.55B | 0.52 | - |
| 2018 | CNY 3.02B | 0.61 | 805.3% |
| 2017 | CNY 2.22B | 0.40 | 103.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 16, 2015.
Who owns Kangmei Pharmaceutical Co Ltd
- Insiders 26.60%
- Institutions 5.46%
- Public & others 67.94%
- Shares outstanding 13.8B
- Free float 11.8B
Kangmei Pharmaceutical Co Ltd company profile
- Company name
- Kangmei Pharmaceutical Co Ltd
- Ticker
- 600518.SHG
- ISIN
- CNE0000017M1
- Exchange
- Shanghai Stock Exchange
- Listed since
- Mar 19, 2001
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,492
- Fiscal year end
- December
- Address
- Taike Road, Shenzhen, China, 518000
- Phone
- 86 75 5331 87777
- Website
- kangmei.com.cn
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. It also engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Shenzhen, China.
Kangmei Pharmaceutical Co Ltd management
8- Mr. Guoxiong OuGM & Director · born 1968
- Mr. Guibo Gong CPADeputy GM & CFO · born 1975
- Mr. Yunfeng ZhouDeputy GM, Secretary to the Board & Director · born 1981
- Mr. Qiyun ChenDeputy General Manager · born 1978
- Mr. Zebin LiAssistant to General Manager · born 1985
- Mr. Xinquan LiuDeputy General Manager · born 1975
- Ms. Jin Jin ZhangAssistant to General Manager · born 1980
- Li Feng TianHead of Accounting Department